Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00457860
Recruitment Status : Unknown
Verified April 2007 by Cambridge Antibody Technology.
Recruitment status was:  Recruiting
First Posted : April 9, 2007
Last Update Posted : April 17, 2007
Information provided by:
Cambridge Antibody Technology

Brief Summary:

RATIONALE: The CAT-8015 immunotoxin can bind tumor cells and kill them without harming normal cells. This may be an effective treatment for chronic lymphocytic leukemia (CLL), prolymphocytic leukemia (PLL), or small lymphocytic lymphoma (SLL that has not responded to chemotherapy, surgery or radiation therapy.

PURPOSE: Phase I dose escalation study to determine the maximum tolerated dose of CAT-8015 immunotoxin in treating patients who have chronic lymphocytic leukemia, prolymphocytic leukemia or small lymphocytic lymphoma that has not responded to treatment

Condition or disease Intervention/treatment Phase
Leukemia Drug: Immunotoxin therapy Drug: CAT-8015 immunotoxin Procedure: Biological therapy Phase 1

Detailed Description:

OUTLINE: Patients receive CAT-8015 IV over 30 minutes on days 1, 3, and 5 followed by rest. Treatment repeats every 4 weeks for up to a total of 10 courses in the absence of dose limiting toxicity, complete response or disease progression. Patients are followed at 1, 3, 6,12,15,18, 21, 24 months following the start of the last treatment cycle.

Cohorts of 3-6 patients each will receive escalating doses of recombinant CAT-8015 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose proceeding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, between16 to 25 new patients will be added to the MTD cohort depending on how well the CAT-8015 is tolerated.

Study Type : Interventional  (Clinical Trial)
Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia (CLL), Prolymphocytic Leukemia (PLL), or Small Lymphocytic Lymphoma (SLL)
Study Start Date : March 2007

Primary Outcome Measures :
  1. Estimate the maximum dose that can be safely administered to a patient
  2. Characterize the toxicity profile of CAT-8015
  3. Study the clinical pharmacology of CAT-8015
  4. Observe anti-tumor activity, if any

Secondary Outcome Measures :
  1. To assess the potential of CAT-8015 to induce antibodies
  2. To Investigate the potential of biomarkers to predict any therapeutic or toxic response

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No



  • Confirmed diagnosis of B-cell leukemia (CLL, PLL or SLL)
  • Measurable disease
  • Patients with chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL) are eligible if they have failed 2 or more prior courses of standard chemotherapy and/or biologic therapy (e.g. Rituxan) and if treatment for progressive disease is medically indicated. Patients with prolymphocytic leukemia (PLL) will be eligible if they have failed at least one prior standard chemotherapeutic regimen. Medical indications for treatment include progressive disease-related symptoms, progressive cytopenias due to marrow involvement, progressive or painful splenomegaly or adenopathy, rapidly increasing lymphocytosis, autoimmune hemolytic anemia or thrombocytopenia and increased frequency of infections.


Performance status

  • ECOG 0-2

Life expectancy

  • Life expectancy of greater than 6 months, as assessed by the principal investigator


  • Patients with other cancers who meet eligibility criteria and have had less than 5 years of disease-free survival will be considered on a case-by-case basis
  • Ability to understand and sign informed consent
  • Female and male patients agree to use an approved method of contraception during the study


  • Documented and ongoing central nervous system involvement with their malignant disease (history of CNS involvement is not an exclusion criterion)
  • History of bone marrow transplant
  • Pregnant or breast-feeding females
  • Patients whose plasma contains either a significant level of antibody to CAT-8015 as measured by ELISA, or antibody that neutralizes the binding of CAT-8015 to CD22 as measured by a competition ELISA.
  • HIV positive serology (due to increased risk of severe infection and unknown interaction of CAT-8015 with antiretroviral drugs)
  • Hepatitis B surface antigen positive
  • Uncontrolled, symptomatic, intercurrent illness including but not limited to: infections requiring systemic antibiotics, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric illness, or social situations that would limit compliance with study requirements

Hepatic function: serum transaminases (either ALT or AST) or direct bilirubin:

  • ≥ Grade 2, unless bilirun is due to Gilbert’s disease

Renal function: serum creatinine clearance ≤60mL/min as estimated by Cockroft-Gault formula

Hematologic function:

  • The ANC <1000/cmm, or platelet count <50,000/cmm, if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy)
  • Baseline coagulopathy > grade 3 unless due to anticoagulant therapy
  • A patient will not be excluded because of pancytopenia ≥ Grade 3, or erythropoietin dependence, if it is due to disease, based on the results of bone marrow studies

Pulmonary function:

  • Patients with < 50% of predicted forced expiratory volume (FEV1) or <50% of predicted diffusing capacity for carbon monoxide (DLCO), corrected for hemoglobin concentration and alveolar volume. Note: Patients with no prior history of pulmonary illness are not required to have PFTs. FEV1 will be assessed following bronchodilator therapy.

Recent prior therapy:

  • Cytotoxic chemotherapy, corticosteriods (except stable doses of prednisone), whole body electron beam radiation therapy, hormonal, biologic or other systemic therapy or investigational therapy of the malignancy for 3 weeks prior to entry into the trial
  • Less than or equal to < 3 months prior monoclonal antibody therapy (i.e. rituximab)
  • Patients who have received or are receiving radiation therapy less than 3 weeks prior to study entry will be not be excluded providing the volume of bone marrow treated is less than 10% and also the patient has measurable disease outside the radiation port

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00457860

United States, California
Tower Hematology Oncology Medical Group Recruiting
Beverly Hills, California, United States, 90211
Contact: Marie Fuerst, RN, MS    310-285-7269      
Principal Investigator: Peter Rosen, MD         
United States, Indiana
Indiana University Cancer Center Not yet recruiting
Indianapolis, Indiana, United States, 46202
Contact: Mary Cangany, RN, CCRP    317-278-4694      
Principal Investigator: Larry Cripe, MD         
United States, Maryland
Warren Grant Megnuson Clinical Center - NCI Clinical Trials Referral Office Recruiting
Bethesda, Maryland, United States, 20892
Contact: NCI Clinical Trials Referral Office    888-624-1937      
Principal Investigator: Robert J Kreitman, MD         
Klinika Hemtologii Uniwersytetu Medycznego (Medical University of Lodz) Not yet recruiting
Lodz, Poland
Contact: Krzysztof Jamoziak, MD    00 48 42 689 5191      
Principal Investigator: Tadeusz Robak, Professor         
Sponsors and Collaborators
Cambridge Antibody Technology

Publications: Identifier: NCT00457860     History of Changes
Obsolete Identifiers: NCT00453284
Other Study ID Numbers: CAT-8015-1002
First Posted: April 9, 2007    Key Record Dates
Last Update Posted: April 17, 2007
Last Verified: April 2007

Keywords provided by Cambridge Antibody Technology:

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Immunologic Factors
Physiological Effects of Drugs